Please login to the form below
RNA interference
This page shows the latest RNA interference news and features for those working in and with pharma, biotech and healthcare.
Moderna CEO makes case for firm’s lofty valuation
Moderna’s specialty is in messenger RNA (mRNA) drugs which are designed to turn a patient’s own cells into drug-manufacturing factories, hijacking the cellular machinery involved in protein production. ... It’s potentially a whole new drug class,
Latest news
-
Orphan drugs dominate FDA's record-breaking year
Other highlights of the year included Alnylam’s hereditary ATTR amyloidosis drug Onpattro (patisiran) becaming the first RNA interference (RNAi) therapy to get a green light from the FDA.
-
NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done
Gaining NICE recommendation would be a major milestone for both companies – Onpattro is Alnylam’s debut product from its RNA interference (RNAi) drug platform, while Tegsedi is similarly Akcea’s first ... product from its antisense drug technology,
-
Moderna files record $500m IPO for RNA pipeline
Could be the largest IPO for a biotech start-up. Moderna Therapeutics, a specialist in messenger RNA-based drugs, has filed a $500m initial public offering (IPO) that would break all ... It’s a different spin on other RNA approaches, such as RNA
-
Alnylam gets EU nod for Onpattro amid pricing backlash
The EMA has cleared Onpattro (patisiran) – the first RNA interference drug approved in the EU – for adult hATTR amyloidosis patients with stage 1 or 2 nerve damage (polyneuropathy), one of the
-
ICER says Alnylam’s Onpattro should cost 90%-95% less
In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’ antisense candidate Tegsedi (inotersen) which is due for an FDA
More from news
Approximately 1 fully matching, plus 31 partially matching documents found.
Latest appointments
-
Silence appoints chief medical officer
These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
-
Senior Medical Writer
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Account Director, Medical Education
-
Salary TBC
- Scientific Director – Medical Communications
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
-
Digital Account Director
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
-
Health Consultant - Brand Comms
-
Competitive Salary
Subscribe to our email news alerts
- Blood disorder specialists Imara raises $63m
- NICE wants to stop saying ‘no’ – but needs pharma’s co-operation
- Three questions that should anchor your brand strategy
- Allergy Tx hit hard as birch pollen product stumbles
- Sanofi gets cardio outcomes claim for Praluent in EU
- Keytruda adds another NSCLC approval in Europe
PMHub
Random42 Scientific Communication
Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...
Latest intelligence
- “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
- The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
- The Future of Pharma sales: fast forward to 2029
- Change is inevitable, and necessary, for growth in business....
- International Women's Day - 8 March 2019
- International Women's Day has been celebrated since its inception in 1911. But how far have we come?...
Quick links
Infographics
